Clinical Trial

Intervention of CAR-T Against Cervical Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2017-11-24; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03356795
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Cervical Cancer
Enrollment 20 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23